Search Hotels in Sausalito

The financial landscape has undergone a tectonic shift in the opening months of 2026, as the long-dormant Russell 2000 index has surged to record highs, marking what many analysts believe is the...

The Great Rotation: Small-Caps Seize Market Leadership in Historic 2026 Breakout

March 25, 2026

VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals ↗

Topics Artificial Intelligence Economy Intellectual Property

January 14, 2026

Via Stocktwits

The Great Rotation: Russell 2000 Outshines Mega-Caps as Domestic Small-Caps Take the Reins in 2026

March 24, 2026

As of March 24, 2026, the financial markets are witnessing a tectonic shift that many analysts have dubbed "The Great Rotation." For the first time in over a decade, the small-cap Russell 2000 index is...

Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline.

Topics Artificial Intelligence Economy World Trade

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗

March 22, 2026

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

3 Companies at the Forefront of the GLP-1 Pill Wars ↗

March 16, 2026

Via MarketBeat

March 16, 2026

Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗

February 27, 2026

This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.

As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the...

Topics Regulatory Compliance

The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026

February 27, 2026

Via Finterra

Topics Economy Intellectual Property

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

February 26, 2026

Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position ↗

February 25, 2026

Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.

This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗

February 25, 2026

Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗

Topics Regulatory Compliance

February 25, 2026

Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.

The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth

Topics Regulatory Compliance

February 17, 2026

In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion...

Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.

Topics Earnings Economy

Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗

February 17, 2026

Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition

February 06, 2026

Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83...

This Healthcare Company Believes Its GLP-1 Pill Could Be "Next in Line" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs. ↗

Topics Earnings Economy

February 05, 2026

Structure Therapeutics has a promising GLP-1 drug that is about to enter phase 3 trials.

A company controlled by the Johnson family sold thousands of shares of this clinical-stage biopharmaceutical company, but that hasn't stopped the pharmaceutical stock from surging.

A 10% Owner Of Structure Therapeutics Shed Shares ↗

January 13, 2026

It's a tough act to follow.

Topics Regulatory Compliance

Can This Stock Double Again in 2026? ↗

January 11, 2026

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List ↗

Topics Artificial Intelligence Economy Intellectual Property

January 05, 2026

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

Via Stocktwits

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

As 2025 draws to a close, the "Magnificent Seven" era of market dominance is facing its most significant challenge yet. While the first half of the year was characterized by a relentless surge in...

Topics Artificial Intelligence ETFs Economy

The Case for Small-Cap Diversification: Why Investors are Looking Beyond Mega-Cap Tech

December 23, 2025

Novo Nordisk Breaks the Mold: Oral Obesity Breakthrough Sends Shares to New Heights as Pharma Landscape Shifts

Topics Artificial Intelligence Economy

December 23, 2025

BAGSVAERD, Denmark — In a landmark decision that has sent shockwaves through the global pharmaceutical industry, Novo Nordisk (NYSE:NVO) has secured U.S. Food and Drug Administration (FDA) approval for...

As 2025 draws to a close, the financial landscape has undergone a seismic shift that few predicted at the start of the year. For the first time in over half a decade, the dominant narrative of "Big...

Topics Economy

The Great Rotation: Small-Caps Seize the Spotlight as Mega-Cap Fatigue Sets In

December 22, 2025

The Great Rotation: Small-Cap Growth Surges as Investors Ditch Defensive Safety for Post-Fed Gains

Topics Economy

December 18, 2025

The financial markets are witnessing a historic "Great Rotation" this December, as the era of defensive posturing and mega-cap concentration appears to be giving way to a broad-based growth rally....

NEW YORK — In a dramatic shift that has recalibrated the pulse of Wall Street, the Russell 2000 index has finally staged its long-awaited breakout, signaling a definitive end to the years-long...

Topics Artificial Intelligence ETFs Economy

The Great Rotation: Small-Caps Break Out as Russell 2000 Hits Record Highs in Late 2025

December 18, 2025

Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Topics Artificial Intelligence ETFs Economy

December 17, 2025

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs

December 11, 2025

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

December 09, 2025